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BACKGROUND: Many clinical trials show no overall benefit. We examined futility analyses applied to trials with different effect sizes.
METHODS: Ten randomised cancer trials were retrospectively analysed; target sample size reached in all. The hazard ratio indicated no
overall benefit (n¼ 5), or moderate (n¼ 4) or large (n¼ 1) treatment effects. Futility analyses were applied after 25, 50 and 75% of
events were observed, or patients were recruited. Outcomes were conditional power (CP), and time and cost savings.
RESULTS: Futility analyses could stop some trials with no benefit, but not all. After observing 50% of the target number of events,
3 out of 5 trials with no benefit could be stopped early (low CPp15%). Trial duration for two studies could be reduced by
4–24 months, saving d44 000–231 000, but the third had already stopped recruiting, hence no savings were made. However,
of concern was that 2 of the 4 trials with moderate treatment effects could be stopped early at some point, although they
eventually showed worthwhile benefits.
CONCLUSIONS: Careful application of futility can lead to future patients in a trial not being given an ineffective treatment, and should
therefore be used more often. A secondary consideration is that it could shorten trial duration and reduce costs. However, studies
with modest treatment effects could be inappropriately stopped early. Unless there is very good evidence for futility, it is often best to
continue to the planned end.
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Randomised phase III trials are usually based on several hundred
or thousand subjects. New interventions are often found to be
ineffective, or the observed effect is lower than expected and
clinically unimportant, despite preliminary evidence that it could
be beneficial. If an intervention is ineffective, it is worth
considering whether the trial could have been stopped earlier
after examining interim data, thus avoiding the recruitment of
additional subjects and giving them an ineffective therapy,
particularly if there are side effects. Also, the trial treatment could
be stopped among those who are already taking it. Stopping for
futility has other potential advantages, including savings in staff
and financial resources.
Stopping trials early for futility has been discussed as far back as
the 1980s (Halperin et al, 1982; Lan et al, 1982; Lan and Wittes,
1988), and work in this area is ongoing (Whitehead and Matsushita,
2003; Pocock, 2006; Lachin, 2009). There appears to be an increasing
number of trials that incorporate futility, either in the protocol or
the Independent Data Monitoring Committee (IDMC) requests such
analyses during the trial. The Food & Drug Administration, for
example, gives some guidance on this (FDA, 2006).
Futility methods involve using earlier results from patients
recruited up to a specific point, to make assumptions about future
data, so there will be limitations to this. For example with time-to-
event outcomes, the assumption of proportional hazards could be
violated during the trial. The two main methods to assess futility
are group sequential methods and conditional power (CP)
(Whitehead and Matsushita, 2003; Snappin et al, 2006; Hughes
et al, 2009). There are various approaches to futility analysis based
on CP (Halperin et al 1982, Lan et al 1982; Lan and DeMets, 1983;
Lan and Wittes, 1988). Other approaches include a Bayesian
method to estimate an ‘average’ CP, called predictive power
(Spiegelhalter et al, 1986; DeMets, 2006) and the use of a phase II
surrogate end point in a phase III trial (Herson et al, 2011).
The Cancer Research UK and UCL Cancer Trials Centre has
conducted clinical trials for many years, of which several have not
shown a worthwhile benefit. We retrospectively examined futility
analyses in these trials.
MATERIALS AND METHODS
Ten randomised phase III trials of superiority were included, in
which the target sample size was reached in all (none had stopped
early); Table 1. These trials were all of those on which the authors
had worked that showed either no effect (n¼ 5), a moderate effect
(n¼ 4) and one additional study was chosen with a large benefit,
for comparison. We aimed to see whether examining futility would
stop the five ‘negative’ trials early (and if so, what the savings
could be), but not any of the others. In UKHAN, no effect was
shown in patients with prior surgery, whereas those without
surgery did benefit, so we regarded them as two separate trials
(UKHAN_1 and UKHAN_2, respectively). In ZIPP, results for two
endpoints were used to show how different results could arise.
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The CP is the chance of getting a statistically significant result at
the end of the trial given the data so far. At each analysis, the
distribution of future data is assumed to be consistent with the
target hazard ratio (HR) (Snapinn et al, 2006). The CP calculation
incorporates the observed and target number of events, and the
observed and target HR; see Appendix 1 for the statistical methods,
which are described in full elsewhere (Lan and Wittes, 1988;
Proschan et al, 2006). For time-to-event outcomes, CP is usually
based on the expected total number of events. However, one
should be cautious in choosing the denominator of the informa-
tion fraction and it is recommended not to dramatically change it
(Proschan et al, 2006). Royston et al (2003) describe a stopping
rule approach based on the expected total number of events in the
control group, for multiple experimental arms when each is
compared with the control. Generally, the CP should get closer to
100% over time as the observed HR approaches or exceeds the
planned HR (i.e., when there is a real treatment effect), and it gets
closer to 0% for studies of ineffective treatments. The CP should be
low to provide sufficient supporting evidence to stop early, though
there is no standard threshold in practice (Snapinn et al, 2006).
Here, we suggest CPp15%. Stata v10 (College Station, TX, USA)
was used to calculate CP (Appendix 2). We also used the method in
which CP is based on the observed treatment effect, rather than the
target effect, at the interim analysis (Snappin et al, 2006). Although
this method can be used with the other one by the Data Monitoring
Committee to examine the interim results using various assump-
tions, it is not often used in practice. For time-to-event outcomes,
caution should be used when interpreting CP if the proportional
hazards assumption is violated. This is not so much a concern for
calculating the CP, but rather a limitation of the statistic to
measure treatment benefit in the presence of non-proportional
hazards.
Three interim analyses were specified, after 25, 50 and 75% of
events had occurred, or patients had been recruited. Many
researchers trigger the interim analyses on events, but using
patients recruited is also used. Outcomes were: (i) CP,
(ii) the number of patients left to recruit the target sample size
and (iii) cost savings if a trial were stopped early.
If analyses are triggered on a specified percentage of recruited
patients, we allowed some follow-up so that events could occur in
the last patients accrued: 3 months for advanced disease (lung and
biliary tract cancer), and 6 months for the others. Further patients
would be recruited during this time, but with minimal contribu-
tion to the analysis. In addition to this, and also for interim
analyses triggered on a specified percentage of events, we allowed
two extra months, during which the IDMC would meet, discuss the
results, and then make decisions with the trial investigators. Both
allowances are expected in practice.
To provide some estimate of uncertainty when interpreting a
single observed CP from a trial, we also simulated 1000 bootstrap
samples for each trial when 50% patients or 50% events had
occurred. Sampling was with replacement. For each trial, patients
were randomly selected from the trial, such that they could
contribute none or at least once to each of the 1000 bootstrap
samples. The patients were sorted by the date of randomisation
and the date of events where they occurred. Bootstrapping was
Table 1 Summary characteristics and final results of the 10 trials examined
Trial name; reference Cancer
Interventions
examined Trial end point
Target
HR
Target sample
size (events)
Actual trial
size (events)
Observed HR,
95% CI and P-value
(at end of trial)
No evidence of an overall benefit
Study 8; Spiro et al, 2006 Lung
(small cell)
Early vs late
radiotherapy
Overall survival 0.73 316 (252) 325 (271) 1.16 (0.91–1.47);
P¼ 0.23
Study 12; Lee et al, 2009a Lung
(small cell)
Thalidomide
vs placebo
Overall survival 0.78 720 (609) 724 (649) 1.09 (0.93–1.27);
P¼ 0.28
Study 14; Lee et al, 2009b Lung
(non-small cell)
Thalidomide
vs placebo
Overall survival 0.78 720 (609) 722 (665) 1.13 (0.97–1.32);
P¼ 0.12
TOPICAL; Lee et al, 2010 Lung
(non-small cell)
Erlotinib
vs placebo
Overall survival 0.75 664 (550) 670 (644) 0.98 (0.82–1.15);
P¼ 0.77
UKHAN_1a; Tobias et al, 2010 Head and neck SIM vs RT alone
(prior surgery)
Overall survival 0.76 253 (174)b 253 (145) 0.97 (0.70–1.35);
P¼ 0.87
Moderate treatment effect
ACT I; UKCCCR, 1996 Anal Chemoradiation
vs RT alone
Overall survival 0.72c 577 (236)c 577 (236) 0.86 (0.67–1.11);
P¼ 0.25
Over 50s; Hackshaw et al, 2011 Breast 5 vs 2 years
of tamoxifen
Event-free survival 0.79 3012 (895) 3449d (1139) 0.85 (0.76–0.96);
P¼ 0.007
UKHAN_2a; Tobias et al, 2010 Head & neck SIM vs RT alone
(no prior surgery)
Overall survival 0.76 399 (293)b 399 (257) 0.81 (0.63–1.04);
P¼ 0.10
ZIPP; Baum et al, 2006 Breast Goserelin vs
no goserelin
Event-free survival 0.81 2700 (742) 2706 (994) 0.80 (0.71–0.91);
P¼ 0.001
ZIPP; Baum et al, 2006 Overall survival 0.81 2700 (742) 2706 (570) 0.78 (0.66–0.92);
P¼ 0.004
Large treatment effect
ABC02; Valle et al, 2010 Biliary tract Gemcitabine/cisplatin
vs gemcitabine alone
Overall survival 0.73 400 (315) 410 (327) 0.64 (0.52–0.80);
Po0.001
Abbreviations: HR¼ hazard ratio; RT¼ radiotherapy; SIM¼ simultaneous chemoradiotherapy. All HRs are as published, except for three trials whose results were reported after
several years of follow-up (Baum et al, 2006; Tobias et al, 2010; Hackshaw et al, 2011). The HRs above were based on events observed 3 years after the last patient was
randomised, when the first analyses could have been reported (as were the conditional powers in subsequent tables). However, they are very similar to those published. aThe
trial compared RT alone with three chemotherapy regimens, but here we only focus on SIM vs RT. bThe original sample size was based on six trial groups considered together, so
here we use the actual size for the particular patient group and SIM vs RT alone. cBased on the expected 5-year survival (65% vs 55%). The original sample size was based on local
failure (target 260 patients in total), but 577 were actually recruited, so here we use the actual size and number of events. There was a clear benefit for local failure but we use
survival because of the modest treatment effect on this. dThe observed number of patients exceeded the initial target because out of the B4000 patients at registration the
number who were eligible (relapse-free and alive) at 2 years was more than the initial estimate of 3012.
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conducted based on the order in which patients were entered into
the trial, therefore replicating the interim analyses scenario as they
would have occurred prospectively. Each simulation was stratified
by treatment arm so that the number of patients in each arm was
the same as that observed. For each of the 1000 bootstrap samples
we calculated the HR and corresponding CP, in order to assess the
proportion of samples that would indicate stopping the trial early
(i.e., where CP p15%). Cost savings were examined in the five
trials with no overall benefit. The same unit costs were specified
for all studies for comparability, without considering inflation and
increased expenses over time. The costs were applied to the
number of months left to complete the target recruitment at each
interim analysis. Investigational drugs were always provided free
of charge by the manufacturer or health service provider, as were
the costs associated with extra follow-up clinic visits and
assessments. Because only the direct costs of conducting the trial
were considered, any estimates of savings are conservative.
RESULTS
The 10 trials are summarised in Table 1, of which 6 were relatively
large (4500 patients). The observed HRs at the end of the study in
the 5 trials with no overall treatment benefit were either just below
or above 1.0, though one (TOPICAL) showed a clear benefit among
patients who had first cycle erlotinib rash. Among the four trials
with moderate effects, the HRs were no lower than 0.78. The
proportional hazards assumption was met in all trials.
Interim analyses triggered after a specified percentage of
events are observed
None of the five trials with no overall benefit would be stopped
early after observing 25% of events (Table 2). After 50% of events
had occurred, Study 12 and UKHAN_1 could have been stopped
(low CP of 2% and 3% respectively), by which point the percentage
of patients left to complete accrual would be 12% (n¼ 83) and
14% (n¼ 36), respectively. The proportion of samples in which the
CP was expected to be p15% was 83.6% (Study 12) and 78.2%
(UKHAN_1) based on the bootstrap estimates of CP. Therefore, a
decision to stop these trials using CP p15%, suggests 16 and 22%
probability of the trials continuing (Table 3); that is, the converse
percentages. Study 14 also had low CP (15%), but recruitment
would already have finished. After observing 75% of events, these
same three trials had very low CP, but all had finished recruitment.
Study 8 also had low CP, but with only 17% of patients (n¼ 54) left
to recruit. The TOPICAL trial would not have been stopped at any
point, though at 75% of events the CP (17%) was close to our
specified cutoff.
Among trials with a moderate effect, only ACT I had low CP,
after 50 and 75% of events had occurred (CP¼ 4% and 2%).
However, the HR estimates at these times (1.16 and 0.95) are
noticeably different from the final estimate of 0.86, so the interim
results on overall survival (OS) would be misleading and
inconsistent with other trial end points (i.e., local failure, for
which a clear benefit was shown), had the study been stopped
early. None of the other three trials had low enough CP to be
terminated early.
As expected, the trial with the large treatment effect (ABC02)
would not be stopped early for futility at any point.
Interim analyses triggered after a specified percentage of
patients are observed
Table 4 shows the results at each of the three specified time points.
None of the five trials with no benefit had sufficiently low CP
(p15%) after either 25 or 50% of patients were recruited. For
example, even after half the patients were randomised in Study 12
(26% (156 out of 609) of the target number of events observed),
the CP was still 55% and HR¼ 1.07 (final HR¼ 1.09). However,
Table 2 Interim analyses based on a fixed percentage of target events (assumes future data is consistent with the target HR)
Percentage of the total target events observed
25% 50% 75%
Trial
HR (95% CI);
P-value
Conditional
power %
No. of
patients
recruiteda
No. (%) of
patients
left
HR (95% CI);
P-value
Conditional
power %
No. of
patients
recruiteda
No. (%) of
patients
left
HR (95% CI);
P-value
Conditional
power %
No. of
patients
recruiteda
No. (%) of
patients
left
No evidence of an overall benefit
Study 8 0.74 (0.45–1.21);
0.23
72 125 191 (60) 0.88 (0.62–1.25);
0.47
39 187 129 (41) 1.08 (0.81–1.43);
0.61
0.02 262 54 (17)
Study 12 1.13 (0.82–1.56);
0.44
48 447 273 (38) 1.17 (0.94–1.47);
0.17
2 637 83 (12) 1.13 (0.94–1.36);
0.18
o0.01 724 0 (0)
Study 14 0.94 (0.69–1.30);
0.72
73 511 209 (29) 1.05 (0.84–1.31);
0.69
15 722 0 (0) 1.09 (0.91–1.31);
0.36
o0.01 722 0 (0)
TOPICAL 0.94 (0.67–1.31);
0.70
81 266 398 (60) 0.87 (0.68–1.10);
0.24
78 425 239 (36) 0.93 (0.77–1.13);
0.49
17 583 81 (12)
UKHAN_1 1.11 (0.61–2.02);
0.73
19 140 113 (45) 1.10 (0.72–1.67);
0.67
3 217 36 (14) 0.98 (0.70–1.39);
0.92
0.3 253 0 (0)
Moderate treatment effect
ACT I 0.98 (0.59–1.63);
0.93
49 323 254 (44) 1.16 (0.80–1.66);
0.43
4 526 51 (9) 0.95 (0.71–1.27);
0.72
2 577 0 (0)
Over 50s 0.96 (0.74–1.25);
0.75
83 2887 125 (4) 0.83 (0.69–1.00);
0.049
95 3443 0 (0) 0.86 (0.73–1.00);
0.043
89 3449 0 (0)
UKHAN_2 1.05 (0.66–1.66);
0.85
36 194 205 (51) 0.85 (0.61–1.18);
0.33
45 331 68 (17) 0.81 (0.62–1.06);
0.13
49 398 1 (0.3)
ZIPP: EFS 0.76 (0.57–1.01);
0.06
90 1436 1264 (47) 0.85 (0.70–1.04);
0.12
79 2159 541 (20) 0.78 (0.66–0.92);
0.003
99.5 2594 106 (4)
ZIPP: OS 0.98 (0.74–1.31);
0.92
62 2358 342 (13) 0.86 (0.70–1.05);
0.13
76 2691 9 (0.3) 0.78 (0.66–0.93);
0.004
99.5 2706 0 (0)
Large treatment effect
ABC02 0.59 (0.37–0.94);
0.025
93 109 291 (73) 0.68 (0.50–0.94);
0.018
95 268 132 (33) 0.66 (0.51–0.86);
0.002
99.9 381 19 (5)
Abbreviations: CI¼ confidence interval; EFS¼ event-free survival; HR¼ hazard ratio; OS¼ overall survival. ‘No. of patients recruited’ plus ‘no. of patients left’ equals at least the
target sample size. aIncludes patients recruited while the DMEC meeting would be organised.
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four trials could have been stopped early after 75% of patients had
been recruited, where the CP was 0.2%, 3%, 10% and 8%, in Study 8,
Study 12, TOPICAL and UKHAN_1, respectively. At this point,
there remains 22, 9, 10 and 17% of patients to be recruited to
complete the original target for these trials.
Among trials with a modest treatment benefit, there are two
instances when recruitment could have terminated early:
UKHAN_2 (CP¼ 11%; 50% of patients), and ACT I (CP¼ 7%;
75% of patients). Stopping these two trials early would be
particularly concerning because the interim data for OS would
not indicate any benefit at all (HRs 1.12 and 1.29 for ACT I and
UKHAN_2, respectively) – very different from the final estimates
(0.86 and 0.81). After 13 years followup of ACT I HR¼ 0.86, 95%
CI 0.70–1.04 (Northover et al, 2010) and there was a clear
benefit on event-free survival for UKHAN (HR¼ 0.72, P¼ 0.004;
Tobias et al, 2010). For ACT I, at 50% events, about 22% of
bootstrapped CPs were 415% (Table 3), which shows some
uncertainty in any decision to stop early.
Futility assuming future data would be consistent with the
observed HR
Table A1 shows the CP when the futility analyses assume that
data from future patients follow the same distribution as that
observed so far (rather than the original target HR). All of the
other results (observed HR, number of patients recruited, and
number of patients and events left to accrue) are the same as in
Tables 2 and 4.
After 50% recruitment, four trials could be stopped (Study 12,
Study 14, Study 8 and UKHAN), but not TOPICAL. All five trials
had low CP after 75% recruitment. In TOPICAL, the CP is expected
to decrease (given that there was no overall effect), but it was low
at first (6%), then higher (26%) and then low again (0.8%). This is
because the HR at 50% of patients (0.88) happened by chance to be
closer to the target (HR¼ 0.75). However, all four trials with a
moderate benefit could have been stopped early.
Time and cost savings for the trials that showed no
evidence of an overall benefit
When interim analyses are based on percentage of events, the
number of months left is, as expected, lower than when based on
percentages of patients recruited, but there could still be cost
savings (Table 5). For example, Study 12 could be terminated early
after observing 50% of events (CP¼ 2%), but there are only 4 more
months to complete recruitment and the savings associated with
early stopping is d44 000. Overall, after seeing 50% of events, three
trials could be stopped early, avoiding 4–24 more months of
accrual and saving d44 000–231 000 in two of these (Study 12 and
UKHAN_1); in Study 14 no savings are made because recruitment
had already finished.
With the futility analysis at 75% of events, only one trial with
low CP is still recruiting (Study 8), but the savings would be 15
fewer months of recruitment and d144 000 lower costs.
Table 5 also shows the estimated time and cost savings when the
analyses are based on recruited patients. The trials could only be
stopped after 75% of patients had been recruited, with 4–28 fewer
accrual months and d44 000–270 000 lower costs. For example, in
Study 12 only 66 more patients are needed to reach the target
sample size, which actually took only 4 months. Had this study
been stopped early, the savings would be d44 000. However, the
number of months left to complete accrual was 19 for Study 8, 6 for
TOPICAL and 28 for UKHAN_1. Even after recruiting 75% of
patients there could be significant cost savings by stopping early:
d183 000, d58 000 and d270 000, respectively. The observed
monthly accrual rates are an important factor when considering
whether to stop early or not, which was high in Study 12.
DISCUSSION
To the best of our knowledge, this is the first application of futility
analysis to several real phase III oncology trials. Early stopping of
those with an ineffective intervention has obvious appeal –
primarily not exposing further patients to it, when there is no
benefit but there could be side effects. However, we show that the
decision to stop recruitment early is not straightforward (unless
based on safety concerns and there is clearly more harm in one
group than the other). There are trials with no overall benefit that
might not be stopped early, but worse still there are studies with
modest effects that could. Similar conclusions have been found
elsewhere (Barthel et al, 2009). Conducting clinical trials is
expensive and takes several years, so a secondary consideration
is the potential significant savings in accrual time and financial
costs, which could be of interest to funding organisations, but
should be outweighed by the ethical issues. All of these
considerations should be balanced against maximising the sample
size to get a more reliable estimate of the treatment effect;
examination of secondary end points (DeMets, 2006) and
important, pre-specified subgroup analyses; and not missing an
intervention with a moderate benefit, which is still clinically
worthwhile.
Occasionally, by the time there is sufficient evidence for futility,
recruitment is not far from the target, so it is sometimes best to
continue to the end, because the savings in time and costs are
minimal (e.g., Study 12); but only if there is no unacceptable
harm to patients. A further consideration is whether patients
are still on treatment. A trial in which all have finished the trial
treatments, but subjects are in follow-up, could still continue if
there are no concerns over the schedule of clinic assessments.
Continuing follow-up in a trial that has been stopped early has
the advantages of minimising bias and obtaining more data on
adverse events.
The worse situation is for trials where there appears to be no
benefit at an interim analysis, but they do in fact have a moderate
effect. It would be unsatisfactory to stop such trials early because
Table 3 CP based upon 50% patients recruited or 50% events observed,
assuming that future data follows the planned HR distribution, and
subsequent 1000 bootstrap replicates
50% Patients 50% Events
Trial
CP
sample
estimate
(%)a
Percentage
of bootstrap
samples with
CPp15%
(95% CI)
CP
sample
estimate
(%)a
Percentage
of bootstrap
samples with
CPp15%
(95% CI)
No evidence of an overall benefit
Study 8 29 28.9 (26.1–31.7) 39 23.3 (20.7–25.9)
Study 12 55 2.1 (1.2–3.0) 2 83.6 (81.3–85.9)
Study 14 68 0.5 (0.1–0.9) 15 49.3 (46.2–52.4)
TOPICAL 75 3.9 (2.7–5.1) 78 3.4 (2.3–4.5)
UKHAN_1 18 39.6 (36.6–42.6) 3 78.2 (75.6–80.8)
Moderate treatment effect
ACT I 50 5.8 (4.4–7.2) 4 78.2 (75.6–80.8)
Over 50s 92 0 (0–0) 95 0.8 (0.2–1.3)
UKHAN_2 11 60.1 (57.1–63.1) 45 18.3 (15.9–20.7)
ZIPP: EFS 87 0 (0–0) 79 3.0 (1.9–4.1)
ZIPP: OS 66 0 (0–0) 76 4.0 (2.8–5.2)
Large treatment effect
ABC02 96 0 (0–0) 95 0.3 (0.0–0.6)
Abbreviations: CI¼ confidence interval; CP¼ conditional power; EFS¼ event-free
survival; HR¼ hazard ratio; OS¼ overall survival. aThe 50% patients CP sample
estimate is taken from Table 4 and the 50% events sample estimate from Table 2.
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of insufficient patients or events. We give examples (ACT I and
UKHAN_2) where interim HRs are close to or exceed 1.0, with low
CP, but the final HR indicated a clinically important effect.
The results and conclusions of three of the trials with no overall
effect provided useful information after reaching the target sample
size, especially when examining important subgroup analyses.
Study 8, whose results were unexpectedly inconsistent with a
preceding Canadian trial (despite having the same protocol), led to
a systematic review showing that early radiotherapy only improved
survival if patients completed chemotherapy (Spiro et al, 2006).
A post-hoc subgroup analysis in Study 14 (Lee et al, 2009b)
indicated that patients with squamous histology who had at least
stable disease by chemotherapy cycle 3 had an OS HR of 0.71,
and this has led to a randomised phase II trial using another
Table 4 Interim analyses based on a fixed percentage of recruited patients (assumes future data is consistent with the target HR)
Percentage of patients recruited of the total target number
25% 50% 75%
Trial
HR (95% CI);
P-value
Conditional
power %
(number
of events)
No. of
patients
recruiteda
No. (%) of
patients
left
HR (95% CI);
P-value
Conditional
power %
(number
of events)
No. of
patients
recruiteda
No. (%) of
patients
left
HR (95% CI);
P-value
Conditional
power %
(number
of events)
No. of
patients
recruiteda
No. (%) of
patients
left
No evidence of an overall benefit
Study 8 0.61 (0.33–1.15);
0.13
80 (41) 90 226 (72) 0.96 (0.66–1.39);
0.81
29 (111) 166 150 (47) 1.05 (0.78–1.40);
0.77
0.2 (179) 246 70 (22)
Study 12 1.14 (0.66–1.97);
0.64
77 (53) 330 390 (54) 1.07 (0.78–1.47);
0.66
55 (156) 453 267 (37) 1.13 (0.91–1.42);
0.26
3 (315) 654 66 (9)
Study 14 0.93 (0.60 –1.44);
0.73
81 (81) 354 366 (51) 0.97 (0.71–1.32);
0.85
68 (161) 543 177 (25) 1.05 (0.83–1.33);
0.69
21 (280) 714 6 (1)
TOPICAL 0.95 (0.67–1.35);
0.78
81 (129) 249 415 (63) 0.88 (0.69–1.12);
0.29
75 (272) 423 241 (36) 0.93 (0.77–1.12);
0.43
10 (434) 600 64 (10)
UKHAN_1 0.80 (0.34–1.87);
0.60
42 (22) 93 160 (63) 1.06 (0.61–1.85);
0.83
18 (50) 157 96 (38) 1.01 (0.65–1.55);
0.98
8 (82) 210 43 (17)
Moderate treatment effect
ACT I 1.15 (0.51–2.61);
0.74
59 (23) 192 385 (67) 0.93 (0.58–1.50);
0.78
50 (68) 371 206 (36) 1.12 (0.78–1.62);
0.54
7 (114) 510 67 (12)
Over 50s 0.96 (0.46–2.02);
0.92
93 (28) 995 2017 (67) 0.92 (0.63–1.35);
0.68
92 (107) 1970 1042 (35) 1.03 (0.77–1.39);
0.84
81 (173) 2600 412 (14)
UKHAN_2 1.05 (0.55–2.02);
0.87
52 (37) 123 276 (69) 1.29 (0.85–1.94);
0.23
11 (91) 241 158 (40) 0.86 (0.62–1.20);
0.37
42 (148) 333 66 (17)
ZIPP: EFS 0.72 (0.46–1.13);
0.15
87 (79) 926 1774 (66) 0.80 (0.62–1.05);
0.11
87 (223) 1582 1118 (41) 0.81 (0.66–0.98);
0.03
91 (405) 2264 436 (16)
ZIPP: OS 1.14 (0.50–2.59);
0.75
78 (23) 926 1774 (66) 1.16 (0.74–1.81);
0.51
66 (78) 1582 1118 (41) 1.02 (0.75–1.38);
0.91
59 (168) 2264 436 (16)
Large treatment effect
ABC02 0.62 (0.40–0.97);
0.036
92 (81) 124 276 (69) 0.65 (0.46–0.90);
0.011
96 (141) 247 153 (38) 0.69 (0.53–0.90);
0.006
99 (222) 356 44 (11)
Abbreviations: CI¼ confidence interval; EFS¼ event-free survival; HR¼ hazard ratio; OS¼ overall survival. ‘No. of patients recruited’ plus ‘no. of patients left’ equals the target
sample size. aIncludes patients recruited while the first 25, 50 or 75% are being followed up, and also the time for the DMEC to meet.
Table 5 Potential savings (time and costs) associated with the interim analyses shown in Tables 2 and 4 for the five trials in which there was no overall
treatment effect
25% Target 50% Target 75% Target
CP
(%)
Information
fraction
No. of
months left
to complete
recruitment
Costs
saved
(d’000)
CP
(%)
Information
fraction
No. of
months left
to complete
recruitment
Costs
saved
(d’000)
CP
(%)
Information
fraction
No. of
months left
to complete
recruitment
Costs
saved
(d’000)
Events observed
Study 8 72 0.25 67 645 39 0.50 40 385 0.02 0.75 15 144
Study 12 48 0.25 12 133 2 0.50 4 44 o0.01 0.75 0 0
Study 14 73 0.25 7 78 15 0.50 0 0 o0.01 0.75 0 0
TOPICAL 81 0.25 23 221 78 0.50 14 135 17 0.75 7 67
UKHAN_1 19 0.25 51 491 3 0.50 24 231 0.3 0.75 0 0
Patients recruited
Study 8 80 0.16 78 751 29 0.44 50 481 0.2 0.71 19 183
Study 12 77 0.09 18 200 55 0.26 12 133 3 0.52 4 44
Study 14 81 0.13 11 122 68 0.26 6 67 21 0.46 1 11
TOPICAL 81 0.23 24 231 75 0.49 15 144 10 0.79 6 58
UKHAN_1 42 0.13 65 626 18 0.29 47 452 8 0.47 28 270
Abbreviations: CP¼ conditional power. Calendar years of recruitment were: Study 8 (Dec 1992–Oct 2001), Study 12 (May 2003–Feb 2006), Study 14 (Jun 2003–Sep 2005),
TOPICAL (April 2005–April 2009) and UKHAN (Jan 1990–Jun 2000). Annual costs used here were: full-time co-ordinator (d45 000), full-time data manager (d35 000), half-time
administrator (0.5 of d27 000), regulatory support (d10 000), IT support (d5000) and running expenses of d7000. TOPICAL, Study 12 and Study 14 were large, so we allowed
for 1.5 data managers. Costs saved, if the trial is stopped early, are rounded to the nearest d1000.
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antiangiogenic agent in these particular patients. In a prespecified
subgroup analyses in TOPICAL (Lee et al, 2010), OS and PFS were
significantly improved only among those who developed first-cycle
erlotinib rash, but the reliability of these results would have been
less clear if based on fewer patients and events. Continuing to the
planned end in order to have reliable subgroup analyses has
sometimes been used as justification for not conducting futility
analyses, especially if there is unlikely to be an overall effect.
However, there must be clear justification for these subgroup
analyses, acknowledging the problems with data dredging. Also, if
there is a positive treatment effect in one subgroup, when no
overall effect is found, there may be a negative effect in another
subgroup.
Our analysis has several key strengths. First, it is based only on
trials that reached the original target sample size. Second, we use
real clinical trial data, not just statistical simulations. Third, we
took a practical approach to the interim analyses by allowing time
for follow-up and for the IDMC to meet and make decisions with
the trial team. Fourth, the trials had a range of effect sizes and
sample sizes. Fifth, we undertook bootstrap simulation to provide
estimates of measuring uncertainty for any decision to stop early,
in order to support the analyses based on a single CP estimate
from each trial. We are not aware of any previously published
report that has examined the application of futility with all these
considerations in mind.
Stopping a trial early is a crucial decision to be made between
the IDMC and trial team. The evidence should be robust and based
on several pieces of information, not just one statistic, be it the CP
or otherwise. On the basis of our findings, a list of considerations
for stopping for futility is shown in Box 1, so that only truly
‘negative’ trials are likely to be stopped early. It is worthwhile
having two successive interim analyses to see if the data are
consistent, hence strengthening the justification to terminate.
Herson et al (2011) suggest that stopping trials early might miss
late treatment effects and so futility methods should be used with
caution. Freidlin et al (2010) comment on the need to strike a
balance between aggressive and conservative stopping rules,
suggesting a repeated monitoring approach. Overly aggressive
stopping rules in the second half of a study may result in trials with
moderate effects being stopped early. For example, in ACT I (after
50% events) the HR¼ 1.16 and CP¼ 4%, but the bootstrapping
analysis indicates that there is still 22% chance of reaching the
target HR. Conversely, conservative stopping rules may allow trials
to continue past the point of when sufficient evidence to stop early
has been attained.
Assumptions about the distribution of future data and timing of
the interim looks are important. The CP method we used is based
on the target HR (Snapinn et al, 2006). There is another method in
which CP is estimated using the observed HR as the new target.
The problem with this is that the observed HR is likely to be
unreliable early on in the trial. However, CP based on the target
effect size is relatively insensitive to the early results of a trial.
Deciding whether to trigger the interim analysis on proportion of
patients recruited or events observed is also important. The
observed effect size early on in a trial may fluctuate too much and
so be unreliable, especially if there is treatment imbalance (Herson
et al, 2011), and regardless of the method or assumptions used.
Many researchers use percentage of events to trigger the interim
analysis, a reasonable approach given that the statistical analyses
are often influenced most by the number of events, and hence
might be more reliable than percentage of patients. In the set of
trials we examined, futility analyses triggered on events (after 50 or
75%) could stop four out of the five trials with no overall benefit,
and only one trial with a moderate effect. Whereas analyses
triggered on patients could also stop four out of five studies with
no benefit, but 2 trials with a moderate effect. An important
consideration is that analyses triggered on events are more likely
to be based on longer follow-up, so the potential savings are
generally less than analyses triggered on number of patients
(Table 5).
Further research using modelling and simulations could
examine an appropriate frequency of interim analyses, specifying
situations when futility may or may not be appropriate, and which
method(s) are appropriate, including whether to trigger the early
looks on percentage of events or patients observed. Terminology
from medical screening could be useful: detection rate (DR – the
proportion of truly negative trials that are stopped early) and false-
positive rate (FPR – the proportion of trials with modest treatment
effects that are stopped early). A good method will have high DR
and low FPR, and these parameters could be examined in relation
to trial size, the timing of interim analyses, and different statistical
methods. Other authors have discussed futility in relation to falsely
stopping studies (Hughes et al, 2009). Methods examining two or
more end points could also be developed.
In summary, careful application of futility methods can lead to
ineffective treatments not being given to future trial patients, and
this could also lead to shorter trial duration and reduced financial
costs. However, there are situations when the end of the trial is not
far off, so the research team may as well complete it. A major
concern is that there are studies with modest treatment effects
that could be inappropriately stopped early, and a clinically
important effect missed. Therefore, unless there is very clear and
sufficient evidence for futility, it is often best to continue to the
planned end.
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Box 1 Considerations for stopping a clinical trial early for futility
 Futility might not be useful for early-stage cancers that have a good prognosis, where events (e.g., recurrences or deaths) take several years to be
seen. By the time lack of benefit is determined to be reliable, recruitment (and probably treatment) is probably close to finishing.
 There should be a low conditional power (e.g.,p15%), based on the target effect size. The research team and IDMC should agree what they consider
to be low. It is also worth considering estimates of uncertainty (e.g., bootstrapping CPs).
 Effect size should be very close to or above the no effect value (e.g., HR41, possibly with lower 95% CI limit X0.90 or 0.95).
 The IDMC and trial team should agree that enough patients and, importantly, events have been observed so far to produce a reliable effect
(remembering that the trial investigators are likely to want to continue); interim data will be influenced by chance, especially in early analyses.
 There are many more patients left to recruit, or to finish accrual is likely to take many more months (with financial cost considerations).
 Other clinically important end points do not show evidence of a benefit.
 There is no evidence of an effect in important pre-specified subgroups. However, if there is evidence within a subgroup (but not overall), an early
effect could be spurious, especially if not based on many events or patients. Continuing to the end should confirm whether there really is an effect in
the subgroup, and if there is, obtain a better estimate of it.
 The adverse events profile is acceptable (if there are no safety concerns, one might wish to continue to ensure that a modest effect is not missed).
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APPENDIX 1
Equation for calculating conditional power (CP) (Proschan et al,
2006) used in (Table 2).
The CP at a specific time¼ 1–j[(Za/2–E[B(1)|B(t)])/O1 t].
where j is the area under the standard normal distribution
associated with what is in the brackets.
 Za/2 is the Z-value cutoff associated with the target level
of statistical significance (we use a P-value of 0.05, so Za/2
is 1.96).
 B(t) is the transformed Z-statistic (based on a Brownian motion
applied to sequential analyses), i.e., B(t)¼Z(t)Ot.
 E[B(1)|B(t)] is the expected value of B(t) at the end of the trial
(when t¼ 1), given the data observed until point t.
 The information fraction, t, is the number of observed events
so far, expressed as a proportion of the planned number of
events.
General form
Example (TOPICAL trial, after 25%
of patients have been recruited)
n¼Number of events observed
so far
n¼ 129
N¼Target number of events N¼ 550
t¼ n/N (information fraction) t¼ 129/550¼ 0.234
HR_O¼ observed hazard ratio HR_O¼ 0.95
HR_E¼ target (expected)
hazard ratio
HR_E¼ 0.75
ln¼natural logarithms
E½Bð1Þ j BðtÞ ¼ﬃﬃﬃ
n
4
r
 ln 1
HR O
 
 tp
 
þ
ﬃﬃﬃﬃ
N
4
r
 ln 1
HR E
 
ð1 tÞ
" # E½Bð1Þ j BðtÞ ¼ﬃﬃﬃﬃﬃﬃﬃ
129
4
r
 ln 1
0:95
 
 0p :234
" #
þ
ﬃﬃﬃﬃﬃﬃﬃ
550
4
r
 ln 1
0:75
 
0:766
" #
E[B(1)|B(t)]¼ 0.141þ 2.582¼ 2.723
CP¼ 1 f½ðZa/2  E½Bð1Þ j BðtÞÞ/ ð
p
1 tÞ
CP¼ 1f½ð1:96 2:723Þ/ ðp 0:766Þ
¼ 1 f½  0:872
¼ 0:81 ði:e:; 81% Þ
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APPENDIX 2
Stata code for calculating conditional power and also for
generating 1000 bootstrap samples for a trial
Conditional power
The following variables need to be present in the data set for each
interim analysis:
n: the number of events observed up until the interim analysis.
N: the number of planned events at the end of the trial.
t: the information fraction¼ nN.
HR_O: the observed hazard ratio at the interim analysis.
HR_E: the planned hazard ratio.
*Conditional Power, based on planned data (the following
represents two lines of code):
generate con_power_plan¼ (1 normal((1.96 ((sqrt(n/4)
 ln(1/HR_O) sqrt(t))þ (sqrt(N/4) ln(1/HR_E) (1 t))))/sqrt
(1 t))) 100
label variable con_power_plan Conditional power (%) – planned.
Bootstrap sampling
The bootstrap sampling is based upon data at a particular time
point. In our analysis this relates to 25, 50 or 75% events or
patients. That is, this restricts the data set to include only those
patients who have been entered into the study by the specified time
point (see Materials and Methods for further details).
*Bootstrap samples: 1000 replicates, based on generic data
(one line of code):
bootstrap _b N_fail¼ e(N_fail), rep(1000) strata(treat)
saving(trial_bootstrap, replace): stcox treat
Table A1 Conditional power based on a fixed percentage of recruited
patients or events (assumes future data is consistent with the observed
hazard ratio so far
Percentage of patients
recruited of the total
target number
Percentage of
the total target
events observed
Trial 25% 50% 75% 25% 50% 75%
No evidence of a benefit
Study 8 98 1 o0.01 69 9 o0.01
Study 12 o0.01 0.1 o0.01 o0.01 o0.01 o0.01
Study 14 13 3 0.02 8 0.01 o0.01
TOPICAL 6 26 0.8 8 32 1
UKHAN_1 30 0.3 0.3 0.1 0.01 0.01
Moderate treatment effect
ACT I 0.07 5 o0.01 2 o0.01 0.09
Over 50s 9 22 0.4 6 88 72
UKHAN_2 0.5 o0.01 17 0.3 21 38
ZIPP: EFS 99.6 90 91 98 64 99.8
ZIPP: OS o0.01 o0.01 0.6 3 55 99.8
Large treatment effect
ABC02 99.6 99.4 99.3 99.9 98 100
General form
Example (TOPICAL trial, after 25%
of patients have been recruited)
n¼Number of events observed
so far
n¼ 129
N¼Target number of events N¼ 550
t¼ n/N (information fraction) t¼ 129/550¼ 0.234
HR_O¼ observed hazard ratio HR_O¼ 0.95
E½Bð1Þ j BðtÞ ¼
ﬃﬃ
n
4
p  ln 1HR O 	= ﬃﬃtp E½Bð1Þ j BðtÞ ¼ ﬃﬃﬃﬃﬃ1294q  ln 10:95 	/ ﬃﬃﬃﬃﬃ129550q ¼ 0:601
CP¼ 1 f za/2E½Bð1Þ j BðtÞ ﬃﬃﬃﬃﬃﬃﬃ
1 tp

 
CP¼ 1f 1:960:601ﬃﬃﬃﬃﬃﬃﬃﬃ
0:766
p

 
¼ 1fð1:553Þ¼ 0:06ði:e: 6% Þ
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